ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Longer-Term Outcomes from the THINKER and EXPANDER Trials of Transplantation Using HCV-Viremic Kidneys

V. S. Potluri1, F. Naqvi2, P. Reese1, M. Shah1, D. Brown2, S. Prenner1, A. Loupy3, A. Woodards1, P. Abt1, E. Blumberg1, J. Trofe-Clark1, D. Segev2, R. Bloom1, D. Sawinski1, C. Durand2, P. Porrett1, M. Levine1, D. Goldberg4, N. Desai2

1University of Pennsylvania, Philadelphia, PA, 2Johns Hopkins, Baltimore, MD, 3Paris Transplant Group, Paris, France, 4University of Miami, Miami, FL

Meeting: 2020 American Transplant Congress

Abstract number: 282

Keywords: Cadaveric organs, Hepatitis C, Kidney transplantation, Viral therapy

Session Information

Session Name: All Organs: Viral Hepatitis

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:03pm-4:15pm

Location: Virtual

*Purpose: The practice of transplanting HCV-viremic kidneys into HCV-negative recipients has become more common, but longer-term outcomes have not been reported. We present data on kidney transplant recipients from the THINKER (NCT02743897) and EXPANDER (NCT02781649) trials, which launched in the year 2016.

*Methods: In EXPANDER, 10 recipients received elbasvir-grazoprevir just prior to transplantation and DAA therapy was tailored as needed after viral genotyping. For the 35 THINKER recipients, only HCV genotype 1 or 4 donor organs were accepted and elbasvir-grazoprevir therapy was started on day 3 post-transplant. Using a multi-dimensional prediction score (iBox) we estimate the projected long-term allograft survival.

*Results: The median age at transplant was 63 years and 13 recipients (29%) were black race. The median time to transplant from initial wait-listing was 342 days [IQR 166-521 days]. All patients achieved SVR-12. Twelve recipients (27%) had delayed graft function. One recipient experienced rejection and none had primary graft failure. One THINKER recipient died two years post-transplant of adenocarcinoma considered unrelated to HCV or its therapy. Eight patients (18%) developed BK viremia. At a median follow-up of 30 months [IQR 24-36 months], median eGFR was 61 ml/min [IQR 53-73 ml/min] and the median urine protein-creatinine ratio was 0.14 g/g [IQR 0.1-0.31 g/g]. Seven patients (16%) had developed de-novo DSA – 3 developed class I (MFI range 1000-2200), 5 developed class II (MFI range 2400-14500). Using the iBox, the predicted median allograft survival will be 95% and 90% at 5 and 10-years in the future.

*Conclusions: Several years after trials of transplantation of HCV-viremic kidneys into uninfected patients, recipients have very good allograft function and little evidence of adverse consequences of infection. Multicenter studies with large samples are needed to determine if HCV infection is associated with rare complications.

“$$graphic_”

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Potluri VS, Naqvi F, Reese P, Shah M, Brown D, Prenner S, Loupy A, Woodards A, Abt P, Blumberg E, Trofe-Clark J, Segev D, Bloom R, Sawinski D, Durand C, Porrett P, Levine M, Goldberg D, Desai N. Longer-Term Outcomes from the THINKER and EXPANDER Trials of Transplantation Using HCV-Viremic Kidneys [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/longer-term-outcomes-from-the-thinker-and-expander-trials-of-transplantation-using-hcv-viremic-kidneys/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences